A mechanism-based model for pharmacodynamic effects of dexamethasone (DEX) was incorporated into our model for arthritis disease progression in the rat to aid in identification of the primary factors responsible for edema and bone loss. Collagen-induced arthritis (CIA) was produced in male Lewis rats following injection of type II porcine collagen. DEX was given subcutaneously in single doses of 0.225 or 2.25 mg/kg or 7-day multiple doses of 0.045 or 0.225 mg/kg at 21 days post disease induction. Effects on disease progression were measured by paw swelling, bone mineral density (BMD), body weights, plasma corticosterone (CST), and TNF-α, IL-1β, IL-6, and GR mRNA expression in paw tissue. Lumbar and femur BMD was determined by PIXImus-II dual energy x-ray absorptiometry. Plasma CST was assayed by HPLC. Cytokine and GR mRNA were assayed by quantitative real-time PCR. Indirect response models, druginteraction models, transduction processes, and the 5 th -generation model of corticosteroid dynamics were integrated and applied using S-ADAPT software to describe how dexamethasone binding to GR can regulate diverse processes. Cytokine mRNA, GR mRNA, plasma CST, and paw edema were suppressed following DEX administration. TNF-α mRNA expression and BMD appeared to increase immediately after dosing but were ultimately reduced. Model parameters indicated that IL-6 and IL-1β were most sensitive to inhibition by DEX. TNF-α appeared to primarily influence edema while IL-6 contributed the most to bone loss. Lower doses of corticosteroids may be sufficient to suppress the cytokines most relevant to bone erosion.
Corticosteroids (CS) have long played a role in treatment of rheumatoid arthritis (Hart, 1976; Neeck, 2002) . Therapy with this class of drugs dates back to early 1950 before quantitative methods describing the kinetics and dynamics of drug disposition and treatment effects were considered necessary for drug development and clinical applications. Numerous adverse effects became recognized and thus dose adjustments were often warranted and other drugs were sought to replace chronic CS treatment regimens. However, CS have remained a mainstay in treatment when other drugs fail and often for bridging between alternative treatments.
Furthermore, recent studies employing low-dose prednisolone or methylprednisolone alone or in combination with other small molecule drugs have highlighted the beneficial role of these compounds in preventing irreversible joint erosion (Svensson et al., 2005; Wassenberg et al., 2005; Da Silva et al., 2006) . In the present study quantitative analysis of CS effects on pro-inflammatory cytokine mRNA in a rat model of RA was performed and used to explain differences in concentrations necessary for treatment effects on paw edema versus bone mineral density (BMD), potentially providing insight for optimizing the use of CS in the clinical setting.
A disease progression model for pro-inflammatory cytokine mRNA, glucocorticoid receptor (GR) mRNA, plasma corticosterone (CST), paw edema, and BMD is presented in Part I.
Here we integrate the effects of dexamethasone (DEX) into the disease progression model by assuming that DEX binds to the same receptor as CST and both ligand-receptor complexes mediate the observed responses. Time courses of DEX effects and model fittings are presented for several disease progression markers: tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), interleukin-6 (IL-6), glucocorticoid receptor (GR) mRNA, plasma corticosterone (CST), paw edema, and BMD for various dose regimens. Simulations indicating optimal dosing in rats JPET #137414 5 for protecting BMD, while affecting cytokine expression and paw edema, are presented. The combination of mechanistic disease progression modeling with pharmacodynamic DEX effects provides a systems approach to resolving the role of CS treatment on cytokine suppression and subsequent cytokine effects on paw swelling and bone mineral density, and suggests how optimal doses or combination therapies may be designed using knowledge of cytokine suppression and relevant contributions to disease endpoints.
JPET #137414 6 METHODS Care of animals, induction of arthritis, measurements of paw edema, TNF-α, IL-1β, IL-6 mRNA, GR mRNA, CST, BMD and other details are presented in Part I.
Experimental Design

Dynamics of Cytokine mRNA, GR mRNA, & CST: Low and High Single Dose Dexamethasone
On study day zero 144 male Lewis rats were induced with CIA. Of these 144, 78 rats developed edema in both paws. Animal body weights and paw edema were monitored on study days 0, 7, 9, 12, 15, 17, 19, 21 , and at time of sacrifice. Two groups of 39 rats received either a low dose (0.225 mg/kg) or high dose (2.25 mg/kg) of subcutaneous (SC) dexamethasone on day 21. Four to five animals in each group were sacrificed at 1, 2, 4, 6, 8, 12, 24, 36 , and 48 hours post dose. Animals were sacrificed by aortal exsanguinations and blood was collected in syringes containing sufficient EDTA to yield 1.5 mg/mL (4 mM) final concentration (Samtani and Jusko, 2005) . Samples were centrifuged at 1800 x g for 10 min at 4° C. Plasma was collected and stored at -80° C. Skin was removed from hind paws, the paws were excised above the ankle and flash frozen in liquid nitrogen prior to storage at -80° C.
Bone Mineral Density Dynamics: 7-Day Multiple DEX Administration
An additional 8 healthy rats and 6 induced with arthritis were scanned with the PIXImus II instrument (GE Healthcare, WI) to assess changes in bone mineral density in the femur, paw, and lumbar regions after 7-day DEX administration. Healthy rats were divided into two groups of four and dosed once-daily for seven days with either 0.045 or 0.225 mg/kg SC DEX starting on day 21. The six arthritic rats were dosed once-daily for seven days with 0.225 mg/kg SC DEX starting on day 21. Healthy animals were scanned for the femur, lumbar, and paw regions on days 1, 8, 16, 20, 22, 24, 26, 30, and 33 . Arthritic animals were scanned for the femur, lumbar, and paw regions on days 9, 12, 15, 20, 22, 24, 26, 30, and 33. This article has not been copyedited and formatted. The final version may differ from this version. Paw and body weight data and tissues from preliminary pilot studies in our laboratory and from Part I were also included in the model development. A total of 162 healthy and arthritic rats were used for all paw mRNA measurements. From this 220, 214, and 212 data points were used for TNF-α, IL-1β, and IL-6 mRNA (1-2 paws were used per rat). Plasma corticosterone was assayed from 177 rats (177 data points) and paw edema was determined from 314 rats (4340 data points, 13 points per rat). Bone mineral density was assayed from 46 animals and a total of 1464 data points from 5 different scanned regions were modeled. Only the paw mRNA measures and plasma CST were collected by sparse sampling means. The noninvasive measures, paw edema and bone mineral density, were collected serially.
Pharmacodynamic Model of Dexamethasone Effects in Rat Arthritis
Figure 1 shows a general schematic for the entire arthritis progression model with DEX binding to GR. The structure of the disease progression model and relevant feedback by CST is presented in Part I. In general all equations for cytokine mRNA, GR mRNA, paw edema, and BMD remain unchanged when integrating dexamethasone effects into the model, as it is the CS bound to receptor complex in the nucleus (DR N ) that exerts the effect of both DEX and CST. In this model equal concentrations of corticosterone bound to GR in the nucleus and of DEX bound to GR in the nucleus are treated as the same effectors on cytokine mRNA, GR mRNA and CST.
Equations that govern this binding and distribution of drug bound to GR in the nucleus are modified in the presence of DEX.
Corticosterone and GR dynamics
The modified differential equation and initial condition describing concentrations of free GR in the presence of both CST and DEX is
(1) where k syn_GR is the first-order synthesis rate from GR mRNA and k dgr_GR is the first-order loss rate constant. The parameters k RE_C and k RE_D describe the rates that corticosterone bound to receptor and dexamethasone bound to receptor return from the nucleus. The parameter RF is the fraction of GR that returns intact and active. The values for k dgr_GR and RF were fixed from previous studies (Hazra et al., 2007a; Hazra et al., 2007b; Hazra et al., 2007c (Buchwald, 2007) . The model assumes that CST equilibrium between vasculature and tissue is immediate. Bound CST-receptor complex in the cytosol is
and bound DEX-GR complex in the cytosol is
where k T is the first-order rate constant for translocation of bound CST-GR complex to the nucleus and is reported previously. Concentrations of bound CST-GR complex in the nucleus
and concentrations of bound DEX-GR complex in the nucleus are 
The value of DR N for the presence of the two CS is then calculated as the sum of concentrations of each drug bound to receptor in the nucleus:
The parameters R 0_GR , R 0_DR , and R 0_DRN are defined based on the steady-state baseline conditions as described in Part I.
Production of plasma CST concentrations is up-regulated by inflammation and is correlated with pro-inflammatory cytokines and inhibited by DEX-GR complex in the nucleus.
where k in_CST is the first-order rate constant for the production of CST and IC 50_CST is the amount of DR N_D required to inhibit production of CST 50%. The variable B CYT is the influence of proinflammatory cytokines on CST up-regulation defined as
where β 1 and β 2 are the intrinsic activities of each individual cytokine on CST up-regulation.
Dynamics of Paw Edema and Bone Mineral Density
Pharmacodynamic models of drug effect for paw edema and bone mineral density are as presented in Part I.
Disease State Pharmacokinetics of Dexamethasone
The pharmacokinetic model for dexamethasone concentrations after 0.225 and 2.25 mg/kg SC doses in healthy and arthritic animals was applied to describe the kinetics of SC dexamethasone. Equations and initial conditions describing the amounts of DEX in each compartment are ( )
where A Abs indicates the amount at the absorption site, A pl is the amount of DEX in plasma, A T is the amount in peripheral tissues, k a is the first-order absorption rate constant (5.78 hr -1 ), CL is the plasma clearance (1.05 and 1.19 L·hr 
Model Fitting and Nonlinear Regression Analysis
The pharmacodynamic model was constructed in two phases with the disease progression data and drug effect data modeled simultaneously. The first model fitting phase included both disease progression (Part I) and drug effect data on cytokine mRNA, GR mRNA, and plasma CST. The relevant parameters were obtained and then fixed for the second model fitting phase where paw edema and BMD data from both Part I and Part II were modeled simultaneously.
Drug effect-related data, parameters, and model fitted curves are presented here. Modeling fittings were performed using S-ADAPT (BMSR, University of Southern California, San Diego, CA) as described in Part I. Model simulations were done using Berkeley Madonna Software (University of California, Berkeley, CA) implementing the Rosenbrock (stiff) method for solving differential equations. Simulated values of the BMD at steady-state were used to determine the dose at which the maximal steady-state response after treatment was observed. The initial lower and upper bounds of dose in the numerical bisection algorithm were 0 and 2.25 mg/kg oncedaily. These bounds were narrowed until there was less than a 0.001 mg/kg difference between This article has not been copyedited and formatted. The final version may differ from this version. the upper and lower bounds while keeping the maximum response between these two limits. The three-significant digit was reported as the optimal-dose.
This article has not been copyedited and formatted. The final version may differ from this version. The pharmacokinetics of DEX after intramuscular (IM) administration was studied previously in healthy and arthritic rats (Figure 2) . A pilot study in healthy rats showed concentrations following SC and IM dosing to be identical. Plasma DEX concentrations were measured in samples collected in this study and were in agreement with those from IM dosing.
The same kinetic model for IM administration was applied for healthy and arthritic rats following SC DEX dosing.
Profiles for cytokine mRNA expression following single SC doses of 0.225 or 2.25 mg/kg DEX are shown in Figure 3 . TNF-α mRNA shown in Panel A had an unexpected time course following DEX dosing. There was an abrupt rise followed by a drop returning to a rise above the natural disease progression for both doses, although the inhibition by DEX was maintained longer with the higher dose. The IL-1β mRNA was initially inhibited abruptly and almost completely after both DEX doses; however, the inhibition was maintained near 100% for a longer time with the higher dose. Interleukin-6 was inhibited very rapidly and completely in a similar manner. No difference in drug effects between low and high doses was observed with IL-6, indicating a high degree of sensitivity to CS. Interestingly TNF-α was the only cytokine with increased mRNA expression following DEX. Relevant parameter estimates for drug effects on cytokine mRNA are presented in Table 1 . The IC 50 values for these cytokines were in agreement with the observed responses. The lowest value of 4.5 nM was for interleukin-6
indicating the greatest sensitivity to CS effect, followed by IC 50_IL1β of 32.6 nM, and TNF-α at 550 nM. The release constant for DEX-GR complex from the nucleus (k re_D (hr -1 ) = 0.0498) was also much lower than that of CST-GR complex (k re_C (hr along with model equations. Model fittings captured the profiles fairly well, although there was a general over-prediction of suppression with the low dose and the extent to which the multipledosing would reduce the overall paw edema was also slightly over-predicted. Figure 6 shows bone mineral density progression in the femur and lumbar regions of healthy and arthritic rats following 7 once-daily multiple-dosing of either 0.045 mg/kg in healthy rats or 0.225 mg/kg DEX in healthy and arthritic rats. Early in time there is an increase in BMD from natural growth of the 6-9 week old rats. After the first dose at 504 hours in the arthritic group, there was an initial increase in BMD followed by a further decline. In healthy rats there was a delay of about 100 hours before the effects of DEX were observed on BMD. Unlike for paw edema, DEX is known to regulate other factors besides cytokine mRNA in bone turnover.
This article has not been copyedited and formatted. The final version may differ from this version. The model incorporated DEX effects through both inhibition of osteoblast production and reduced pro-inflammatory cytokine mRNA production. The relevent IC 50 for CS inhibition of osteoblast production is listed in Table 1 inhibited TNF-α production, then TNF-α mRNA would increase when IL-6 concentrations fell.
Based on the in vitro evidence for this suppression, the maximal suppression of TNF-α mRNA was fixed at 30% inhibition (Schindler et al., 1990) . The model then captured both this rise and fall and rise again in TNF-α mRNA response.
That the expression of IL-6 mRNA was highly sensitive to DEX indicates that the decline observed in IL-6 mRNA was related to CST. With increased CST and GR mRNA, DR N was increased sufficiently to cause a drop in IL-6 but not in the other measured cytokine mRNA.
While this explains in part the decline of IL-6 mRNA, it could not be the entire reason. If DR N increased rapidly as in the case of CS dosing, CST would be inhibited almost completely and for a prolonged time, such that when DR N returned to normal and CST remained suppressed, the IL-6 mRNA production would overshoot the measured response. The 'remission' compartment presented in Part I helped capture this decline. It is possible that as the disease develops into a more chronic state there is a shift from the innate to a more humoral immune response, effectively altering concentrations of pro-inflammatory cytokines.
Turnover of GR mRNA after DEX behaved differently than the cytokines. There was an abrupt decline followed by a rebound to values higher than found in the natural disease progression with the low dose. If TNF-α had a larger contribution to GR mRNA up-regulation, then it is possible that this rebound would have been observed. This would have also been seen for the higher dose. A time delay was necessary to account for the slow rate of disease progression that did not plateau as quickly as cytokine mRNAs while a fast drop was observed in response to DEX. Transit compartments accounted for the delayed response to cytokines while allowing the equation describing GR to have a high rate of turnover to reflect rapid drug effects.
Binding of DEX to GR was modeled using literature reported K D values to adjust the binding of CST in the presence of DEX in such a way that only ff gc ·k on_C was fitted for both drugs. This parameter corrects for both the fraction of drug that equilibrates from plasma into tissue and the free fraction able to bind receptor. Distribution is assumed to be instantaneous.
The release rate constants (k re_C , k re_D ) from the nucleus were reasonably estimated compared with the k re for methylprednisolone (MPL, k re_M =1.31 hr -1 ) since CST is less potent than MPL while DEX is more potent. The release constant for DEX-GR complex from the nucleus was also much lower than that of CST-GR complex and MPL-GR complex. If both molecules exert their effects to the same extent through GR in the nucleus then DEX would need to remain bound in the nucleus for a longer duration to yield the differences in observed inhibition of As DEX affects cytokine mRNA expression and not edema directly, it is the inhibition of cytokines that governs the decline in paw edema. In general the model captured that data well with modest over-prediction for the 0.225 mg/kg acute and chronic dosing. This over-prediction may be due in part to the linear additive relationship between cytokine mRNA and paw edema.
If the relationship between cytokines and edema is receptor driven, then a Hill-type effect relationship may be more appropriate. It is also possible that because there are other processes which contribute to edema not included in the model, their effects on up-regulating paw edema are missed. However, altering each signaling pathway alone and simultaneously in different combinations while measuring relevant paw edema is impractical, thus the true effect of appeared protective for BMD (Buchwald, 2007) . Additionally, the model suggests that since lower doses of CS should be given and these doses may be insufficient to suppress TNF-α, a second agent given to either reduce concentrations of TNF-α or inhibit TNF-α effects on inflammation would be beneficial to both edema and BMD responses.
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